中国综合临床
中國綜閤臨床
중국종합림상
Clinical Medicine of China
2015年
12期
1089-1092
,共4页
张正义%朱育华%马洪建%李永军
張正義%硃育華%馬洪建%李永軍
장정의%주육화%마홍건%리영군
老年急性髓细胞白血病%CAG方案%强化治疗
老年急性髓細胞白血病%CAG方案%彊化治療
노년급성수세포백혈병%CAG방안%강화치료
Hypoproliferative acute myeloid leukemia in elderly%CAG%Intensive chemotherapy
目的 观察老年低增生性急性髓细胞白血病(AML)经CAG诱导及缓解后强化治疗的效果.方法 26例老年低增生性AML患者接受CAG方案诱导治疗及15例完全缓解后行强化治疗.初治方案为CAG预激方案,获完全缓解后继续应用AA、DA、HA方案进行化疗.结果 26例患者CAG方案化疗后完全缓解(CR)率53.85%(14/26),部分缓解率19.23% (5/26),总有效率73.08%(19/26).根据CAG方案疗效及完全缓解后有无进行强化治疗,将患者分成3组:完全缓解后强化治疗组(CR1组)、完全缓解后未强化治疗组(CR2组)、未缓解组(NR组,部分缓解患者归入该组),进行生存分析,其中位生存时间分别是13.5个月、8.2个月、4.5个月.各组进行比较,CR1组较CR2组、NR组有较长的生存时间,差异有统计学意义(P值分别为0.041、0.001).CR2组较NR组有较长的生存时间,但差异无统计学意义(P=0.064).化疗中未发现严重出血事件.结论 CAG预激方案诱导对老年低增生性AML有效率较高,而且化疗相关毒副作用小,患者耐受性好.完全缓解后继续适当强化治疗有益于延长患者生存时间.
目的 觀察老年低增生性急性髓細胞白血病(AML)經CAG誘導及緩解後彊化治療的效果.方法 26例老年低增生性AML患者接受CAG方案誘導治療及15例完全緩解後行彊化治療.初治方案為CAG預激方案,穫完全緩解後繼續應用AA、DA、HA方案進行化療.結果 26例患者CAG方案化療後完全緩解(CR)率53.85%(14/26),部分緩解率19.23% (5/26),總有效率73.08%(19/26).根據CAG方案療效及完全緩解後有無進行彊化治療,將患者分成3組:完全緩解後彊化治療組(CR1組)、完全緩解後未彊化治療組(CR2組)、未緩解組(NR組,部分緩解患者歸入該組),進行生存分析,其中位生存時間分彆是13.5箇月、8.2箇月、4.5箇月.各組進行比較,CR1組較CR2組、NR組有較長的生存時間,差異有統計學意義(P值分彆為0.041、0.001).CR2組較NR組有較長的生存時間,但差異無統計學意義(P=0.064).化療中未髮現嚴重齣血事件.結論 CAG預激方案誘導對老年低增生性AML有效率較高,而且化療相關毒副作用小,患者耐受性好.完全緩解後繼續適噹彊化治療有益于延長患者生存時間.
목적 관찰노년저증생성급성수세포백혈병(AML)경CAG유도급완해후강화치료적효과.방법 26례노년저증생성AML환자접수CAG방안유도치료급15례완전완해후행강화치료.초치방안위CAG예격방안,획완전완해후계속응용AA、DA、HA방안진행화료.결과 26례환자CAG방안화료후완전완해(CR)솔53.85%(14/26),부분완해솔19.23% (5/26),총유효솔73.08%(19/26).근거CAG방안료효급완전완해후유무진행강화치료,장환자분성3조:완전완해후강화치료조(CR1조)、완전완해후미강화치료조(CR2조)、미완해조(NR조,부분완해환자귀입해조),진행생존분석,기중위생존시간분별시13.5개월、8.2개월、4.5개월.각조진행비교,CR1조교CR2조、NR조유교장적생존시간,차이유통계학의의(P치분별위0.041、0.001).CR2조교NR조유교장적생존시간,단차이무통계학의의(P=0.064).화료중미발현엄중출혈사건.결론 CAG예격방안유도대노년저증생성AML유효솔교고,이차화료상관독부작용소,환자내수성호.완전완해후계속괄당강화치료유익우연장환자생존시간.
Objective To Explore the therapy of elderly patients with hypoproliferative acute myeloid leukemia.Methods Twenty-six elderly patients with hypoproliferative acute myeloid leukemia had received induction of CAG regimen and 15 cases were treated intensive chemotherapy after complete remission,then if achieving complete remission had received subsequent intensive chemotherapy: stand or reduce AA, DA or HA regimen.Results In 26 cases patients who received CAG regimen,the complete remission rate, partial remis sionrat and the totle total effective rate were 53.85% (14/26), 19.23% (5/26) and 73.08% (19/26), respectively.Accordance with response to CAG regimen and the therapy after complete remission, 26 patients were divided into 3 groups:intensive chemotherapy after complete remission(CR1), non-intensive chemotherapy after complete remission(CR2) and non-remission(NR, including partial remission patients).The median overall survival of CR1 ,CR2 and NR were 13.5 months, 8.2 months, and 4.5 months, respectively.There was higher median overall survival of CR1 group than CR2 and NR groups (P =0.041,0.001, respectively).There was higher OS of CR2 group than NR group (P =0.064).No serious bleeding events were found in chemotherapy.Conclusion CAG regimen was an effective and little adverse effect regimen for the treatment of elderly H-AML,and with well tolerance in patients.Advisable intensive chemotherapy can prolong the patient's survival time after complete remission.